Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. (31st December 2022)

• Record Type: Journal Article
• Authors: Tonneau, Marion; Nolin-Lapalme, Alexis; Kazandjian, Suzanne; Auclin, Edouard; Panasci, Justin; Benlaifaoui, Myriam; Ponce, Mayra; Al-Saleh, Afnan; Belkaid, Wiam; Naimi, Sabrine; Mihalcioiu, Catalin; Watson, Ian; Bouin, Mickael; Miller, Wilson; Hudson, Marie; Wong, Matthew K.; Pezo, Rossanna C.; Turcotte, Simon; Bélanger, Karl; Jamal, Rahima; Oster, Paul; Velin, Dominique; Richard, Corentin; Messaoudene, Meriem; Elkrief, Arielle; Routy, Bertrand
• Is Part Of: Oncoimmunology. Volume 11:Number 1(2022)
• Publication Date: 2022-12-31
• Subjects: Metastatic melanoma -- non-small cell lung cancer -- helicobacter pylori -- onco-immunology -- microbiome -- immune checkpoint inhibitor therapy; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2022.2096535
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that Helicobacter pylori seropositivity was associated with a negative prognosis in patients amenable to ICI. In 97 patients with advanced melanoma treated with ICI, we assessed the impact of H. pylori on outcomes and microbiome composition. We performed H. pylori serology and profiled the fecal microbiome with metagenomics sequencing. Among the 97 patients, 22% were H. pylori positive (Pos). H. pylori Pos patients had a significantly shorter overall survival ( p = .02 ) compared to H. pylori negative (Neg) patients. In addition, objective response rate and progression-free survival were decreased in H. pylori Pos patients. Metagenomics sequencing did not reveal any difference in diversity indexes between the H. pylori groups. At the taxa level, Eubacterium ventriosum, Mediterraneibacter (Ruminococcus) torques, and Dorea formicigenerans were increased in the H. pylori Pos group, while Alistipes finegoldii, Hungatella hathewayi and Blautia producta were over-represented in the H. pylori Neg group. In a second independent cohort of patients with NSCLC, diversity indexes were similar in both groups and Bacteroides xylanisolvens was increased in H. pylori Neg patients. Our results demonstrated that the negative impact of H. pylori on outcomes seem to be independent from the fecal microbiome composition. These findings warrant further validation and development of therapeutic strategies to eradicate H. pylori in immuno-oncology arena.